Glucose Health, Inc.
Fiscal 2021 6-Month
Update; Zero Debt, Zero
Liabilities, Fully Diluted
Share Count Reduced by
1/3.
BENTONVILLE,
AR -- August 24, 2021 -- InvestorsHub NewsWire
-- Glucose
Health, Inc. (OTC:
"GLUC")
("Company") is pleased to expand
upon key
financial
information
pertaining
to the
first six months of fiscal
2021,
presented
in
its June
30th
financial
report posted
at OTCMarkets.com.
Zero
Debt
At
the inception
of Glucose
Health, Inc.'s
current
business
operations
involving
the manufacture and distribution of GLUCODOWN® branded
products,
management
implemented
a long-term
debt
reduction
strategy
with the
objective
of
eliminating
all debt
obligations
on
the
balance
sheet,
systematically
over a
period of years. To the
present date,
dozens of
financial
obligations
and
entanglements have
been
repaid
or
otherwise
settled
and
retired.
For
the first time in its corporate history, Glucose Health,
Inc. is
now
a debt
free company.
Reduction of
Share Count by 1/3
Certain
of Glucose
Health, Inc.'s
(now
retired)
debts
were
convertible into millions
of shares
of common
equity. By
adhering
to its
long-term
debt
management
strategy,
the
Company successfully
prevented
tens of millions of
potentially
dilutive
shares from
being issued.
The
result is the
Company's
equity
structure
may
now
be
considered
among the most straightforward,
transparent,
and
attractive of any
development stage company quoted by OTCMarkets.
Today,
Glucose
Health, Inc. has
22,128,632
fully
diluted common
shares,
of
which 13,848,630
are
already
issued
and 8,280,002 are
potentially issuable.
Zero
Liabilities
At
June 30, 2021, Glucose
Health, Inc.
reported
zero
liabilities
on its
balance sheet.
The
genesis of this
result
dates
to the
first production run of GLUCODOWN®
in the
last quarter of 2017. At
that time, management
implemented
a
long-term
strategy
of
prioritizing
cash-in-advance
payments
to its
suppliers for raw materials and contract
manufacturing expenses.
By
maintaining low (or
zero)
accounts
payables,
management
avoided
the need to supplement working capital with
supply
chain financing.
Today,
the
Company maintains
an enviable
track-record,
relative
to other
publicly traded beverage and
nutritional
supplement
companies,
of
having
declined
every
offer
of
inventory
financing,
purchase
order
financing or
factoring
(the
pre-selling
of
a
company's receivables)
from supply
chain finance
companies
which
specialize
in
such arrangements
(often
at
usurious
rates
of
interest).
In
contrast, to enhance
working
capital flexibility
Glucose
Health, Inc. entered
into an agreement with Citibank,
N.A. ("Citibank")
in
2017,
for
early
invoice
payment
(not
traditional
factoring).
Under
this
program, which
continues in
place to the
present date,
Glucose
Health, Inc. receives
payment
for certain
of its invoices,
from
Citibank,
typically
one
week
after
their
issuance.
The
interest
rate charged
by
Citibank is
a
small
premium to the Federal Reserve Bank
of New
York's overnight discount rate and
is
on-par
with similar
financing
offered
to large NASDAQ
or
NYSE listed companies.
About Glucose
Health, Inc. (OTC:
GLUC)
With
a
focus
on creating delicious beverages
nutritionally appropriate1 for
the nation's 100+ million2 pre
and Type-2 diabetics, Glucose
Health, Inc., the manufacturer of GLUCODOWN®, is
uniquely
positioned
among all
emerging beverage
companies in America. The
GLUCODOWN®
brand
is
the
market leader in
an
entirely new beverage
category
– functional,
diabetic
friendly, beverages. Glucose
Health, Inc. is a publicly traded company with the ticker symbol
OTC: GLUC.
To buy
GLUCODOWN® visit our Amazon Store at www.amazon.com/glucodown
Like us on
Facebook at www.facebook.com/glucodown
For more
GLUC information visit
www.glucosehealthinc.com
1
For
citations visit www.glucodown.com/clinical-data
2
National Diabetes Statistics Review, 2020;
Centers for Disease Control and Prevention, Department of Health
and Human Services
This news release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and
while
Glucose
Health, Inc. is not subject to the 1934 Securities and Exchange
Act, contains forward-looking statements within the meaning Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,
"possible," "probable, "believes," "seeks," "may, "will, "should,"
"could" or the negative of such terms or other similar expressions.
Actual results may differ materially from those set forth in this
release due to the risks and uncertainties inherent in the
Company's business. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary
statement and the Company undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
Contact:
Murray
Fleming
Glucose Health,
Inc.
info@glucosehealthinc.com
(479)
802-3827